Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...
In his Sunday column, Jim Cramer explores the dominance of tech stocks and the upside potential that still remains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results